Navigation Links
Antiplatelets: 1 person, 1 dose?
Date:4/14/2011

Montreal, April 14, 2011 An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention (PCI). The results of the GRAVITAS trial conducted to determine whether high-dose clopidogrel is superior to standard-dose therapy for the prevention of cardiovascular events after percutaneous coronary intervention in patients with high on-treatment reactivity, have been published recently in the Journal of the American Medical Association.

The GRAVITAS (Gauging Responsiveness with A VerifyNow assay Impact on Thrombosis And Safety) study showed no benefit of double-dose compared with standard-dose clopidogrel and the results refute the strategy of uniformly doubling the dose of clopidogrel over six months for patients with high on-treatment platelet reactivity after PCI with drug-eluting stent. In the multicenter, randomized, double-blind, active-control trial, the use of high-dose compared with standard-dose clopidogrel did not reduce the incidence of adverse cardiac events such as death, nonfatal myocardial infarction or stent thrombosis.

"The results of GRAVITAS are surprising because they do not support a uniform treatment strategy of high-dose clopidogrel in patients with high on-treatment reactivity." said Dr. Jean-Franois Tanguay, interventional cardiologist at the Montreal Heart Institute, professor of medicine at the Universit de Montral and lead investigator in Canada. "Personalized medicine merits further investigation. We need to assess alternative treatment strategies incorporating platelet function testing as opposed to prescribe a fixed, higher dose."

Between July 2008 and April 2010, 2214 patients from 83 sites in North America had high on-treatment reactivity after being screened with platelet function testing 12 to 24 hours after PCI. They were randomly assigned to either higher (double-dose) or standard-dose clopidogrel for six months after drug-eluting stent implantation. An additional 586 patients without high on-treatment reactivity were selected at random and assigned to treatment with standard-dose clopidogrel. Clopidogrel exposure prior to enrollment was similar across all 3 treatment groups.

At six months, the rate of death from cardiovascular causes, nonfatal myocardial infarction or stent thrombosis was not different with high-dose (25 of 1109 patients) compared with standard-dose (25 of 1105 patients) clopidogrel in patients with high on-treatment reactivity. ''These low event rates reflect the excellent results we can obtain with drug-eluting stents'' said Dr. Tanguay.


'/>"/>

Contact: Julie Chevrette
julie.chevrette@icm-mhi.org
514-376-3330 x2641
Montreal Heart Institute
Source:Eurekalert

Related medicine news :

1. Drug addicts get hooked via prescriptions, keep using to feel like a better person, research shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , ... the world with an estimated 5000 perioperative nurses in attendance to study ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin ... of a new DRTV campaign with Belly Bands. , Having a dog is great—except ... to puppy pads and find nothing works, get Belly Bands, the easiest way ...
(Date:2/5/2016)... ... 05, 2016 , ... Love is in the air at King Kullen! The ... and packaging. This staple for Valentine’s Day is a must-have, and can be picked ... Day, not only are long-stem roses available, but also other flower bouquets, elegantly wrapped ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
(Date:2/4/2016)... SIOUX FALLS, S.D. , Feb. 4, 2016 ... patient and guest technology solutions, today announced that ... SONIFI Health Senior Living Engagement System. The system ... information tool that residents access through a tablet ... --> The resident engagement system provides access ...
Breaking Medicine Technology: